Biotech Values

[bladerunner1717]

re: GERN, INCY

PGS,

I don't want to get into any arguments with you about Jakafi, but I will say that one of the things I've learned from the great posters on this board is that there is a world of difference between the way that Ph.D-types and biostatistical guys and medical research guys think about these issues and the way that M.D. clinicians think about them. I try to learn from both, and that's why I appreciate the input of you and Clark and jq1234 and Peter and Dew and others. I think I'll leave it at that.

Since I suffer from leukemia, these aren't just academic or investment issues for me.

BTH asked what I believe is really the crucial question, beyond the nit-picking of the definitions of CR's, PR's, CI's and the like. The same question was asked on the CC: What are the chances that changes in the underlying neoplasm will lead to changes in the symptomology? Scarlett was pretty definite in his answer (about the only time he was remotely definite at all; this CC will not inspire investor confidence) when he said you can almost assuredly expect symptoms to improve based on the changes that Tefferi has identified in the abstract.

Bladerunner